USPTO serial 88449114
ICHNOS SCIENCES
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- GORAN, BRADLEY TAYLOR
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ICHNOS SCIENCES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.1100 New York Avenue, NWWashington, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cosmetic soaps; Skin soaps; shampoos; sunscreen for cosmetic use; perfumery; essential oils; body powder; cosmetics; anti-aging creams; hair lotion; cosmetic skin care preparations; skin creams; skin moisturizing gel; face wash; moisturizing body lotions; and non-medicated mouthwashes | ACTIVE | — |
| 005 | Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; medical and pharmaceutical preparations, namely, inhaler preparations for treatment of Chronic obstructive pulmonary disease (COPD); Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, and for the treatment of inflammatory disorders, and for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical and biological preparations for the treatment of cancer; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; medicated skin care preparations; medicated skin care preparations, namely, gels; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma; preparations for therapeutic or medical purposes, namely, therapeutic medicated skin preparations for treatment of skin diseases; decongestant nasal sprays | ACTIVE | — |
| 010 | Medical apparatus and instruments, namely, spirometers; medical devices, namely, inhalers sold empty, nebulizers; medical devices, namely, autoanalysers; chromatographic medical diagnostic apparatus | ACTIVE | — |
| 035 | Campaign for patient support program, namely, promoting public awareness for patients with cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases | ACTIVE | — |
| 041 | Educational services, namely, providing workshops and seminars in the fields of cancer treatment, oncology, immunology and pain management; Publication of journals featuring research articles and clinical trials for pharmaceutical preparations; education services, namely, conducting online instruction and courses in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; provision of educational content, namely, providing on-line instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; training in the use and operation of medical devices, medical imaging apparatus and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions, and training programs in the field of pharmaceutical products, healthcare and medical diseases, disorders and related treatments; educational services, namely, providing non-downloadable webinars in the field of health and medical information and distribution of course material in connection therewith; education services, namely, developing, arranging and conducting educational programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine; providing training programs and developing training programs relating to the use and operation of medical devices, medical research apparatus and consultation relating thereto; providing online publications, namely, instructional materials in the nature of worksheets and textbooks, featuring study materials in the field of pharmaceutical products, healthcare and medical disease, disorders and related treatments; conducting educational seminars in the fields of healthcare, the use of pharmaceuticals, and medical devices, medical research, surgery, medical science and medicine | ACTIVE | — |
| 042 | Scientific research for medical purposes in the field of oncology, pain management, dermatology, diabetology, respiratory diseases, biosimilars; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; chemical, pharmaceutical, nutraceuticals and nutritional science, dermo-cosmetic and biotechnology analysis and research; design and testing for new product development; Diagnostic product testing and analysis, namely, medical research and product research for industrial uses; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services, scientific research services for medical purposes including and not limited to bacteriological research services, biomedical research services, laboratory research services, clinical trial services, pharmacological research services, medical research laboratory services, scientific and technological services and research and design relating thereto | ACTIVE | — |
| 044 | Providing information in the field of medicine and health in the field of oncology, pain management, dermatology, diabetology, respiratory diseases and dietetic advisory services; medical services in the field of oncology, pain management. dermatology, diabetology, respiratory diseases and dietetic advisory services; medical assistance in the field of oncology, pain management, dermatology, diabetology, respiratory diseases and dietetic advisory services; hygiene care for human beings in the field of oncology, pain management, dermatology, diabetology, respiratory diseases and dietetic advisory services; medical clinic services; dietetic advisory services; disseminating medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases | ACTIVE | — |
| 045 | Licensing of patents, trademarks and intellectual property | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glenmark Pharmaceuticals Limited
- Other trademarks owned by Glenmark Pharmaceuticals Limited
- Other trademarks owned by ICHNOS SCIENCES SA
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named ICHNOS SCIENCES
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 30, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 29, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 22, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 21, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 21, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 8, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 8, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 16, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 14, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 14, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 14, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 28, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 26, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 26, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 26, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 7, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 7, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Sep 7, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 7, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 29, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 27, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 27, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 27, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 14, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 28, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 26, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 26, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 26, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 28, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 3, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 3, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 12, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 27, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jan 24, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 24, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 24, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 14, 2020 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 8, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Sep 19, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 19, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 19, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 19, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 17, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 7, 2019 | CEPE | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED | — |
| Sep 7, 2019 | ALIE | ASSIGNED TO LIE | — |
| Sep 6, 2019 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 6, 2019 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Sep 6, 2019 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Aug 16, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 12, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 31, 2019 | NWAP | NEW APPLICATION ENTERED | — |